GlassScriptPhysician profile
Matthew S Markis
NPI 1780944470
$4,022.68
in general payments reported to CMS, 2019-2025
21 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $121 · 2021: $25.00 · 2022: $315 · 2023: $227 · 2024: $1,112 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.66 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $422.63 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $414.89 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $302.13 | 2022-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $298.61 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $157.11 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $134.88 | 2020-2025 | Trintellix |
| Neos Therapeutics, LP | $131.67 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Teva Pharmaceuticals USA, INC. | $127.56 | 2019 | |
| Alkermes, INC. | $103.16 | 2022-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $99.10 | 2020 | |
| Collegium Pharmaceutical, INC. | $86.20 | 2025 | Jornay Pm |
| Allergan, INC. | $73.75 | 2019 | |
| Axsome Therapeutics, INC. | $69.97 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $57.72 | 2024-2025 | Quviviq, Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $54.51 | 2019-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $25.42 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.20 | 2025 | Cobenfy |
| Almatica Pharma LLC | $21.52 | 2024 | Loreev Xr |
| Adlon Therapeutics L.P. | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Markis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.